WFM
ALNY icon

Wilmington Funds Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Wilmington Funds Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		$629K Sell
9,960
-2,975
-23% -$177K 0.06% 293
2014
Q1 		$868K Sell
12,935
-2,694
-17% -$209K 0.09% 224
2013
Q4 		$1M Buy
15,629
+4,259
+37% +$254K 0.1% 235
2013
Q3 		$728K Buy
+11,370
New +$567K 0.07% 284

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Wilmington Funds Management's ALNY Position: Q2 2014 in Review

Wilmington Funds Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 23% in Q2 2014, selling an estimated $177K and leaving 9,960 shares worth $629K. The position accounts for 0.06% of the portfolio, ranked #293.

Wilmington Funds Management first reported a position in ALNY in Q3 2013 and has held it in 4 quarters since. The position peaked at $1M in Q4 2013. 194 funds tracked by Wall St. Rank hold ALNY as of Q2 2014.

  • Wilmington Funds Management held 9,960 shares of Alnylam Pharmaceuticals worth $629K as of Q2 2014.
  • Wilmington Funds Management sold 2,975 Alnylam Pharmaceuticals shares in Q2 2014, an estimated $177K.
  • Alnylam Pharmaceuticals made up 0.06% of Wilmington Funds Management's portfolio in Q2 2014, its #293 holding.
  • Wilmington Funds Management first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 4 quarters since.
  • Wilmington Funds Management's Alnylam Pharmaceuticals position peaked at $1M in Q4 2013.
  • 194 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2014.

Based on Wilmington Funds Management's 13F filing for Q2 2014, filed 13 Aug 2014.